NEW YORK , May 2, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today that it has added a third treatment arm to its first pivotal Phase III study of Iferanserin (VEN 309), the first prescription product candidate for the treatment of hemorrhoids.

Company to Host Conference Call on Monday, March 21 at 8:30 AM ET

Background Information to Improved FDA-Recommended Endpoints Proposed for Phase III Hemorrhoid Study

NEW YORK , March 3, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that it has selected inVentiv Clinical Solutions to manage its Phase III pivotal trial with Iferanserin

NEW YORK , Feb. 7, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, announced today that Dr. Russell Ellison , the company's president and chief executive officer will be presenting at the

NEW YORK , Feb. 1, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced the completion of its clinical development staffing. Ventrus has contracted Mohan Kabadi , Ph.D.

Underwriters Exercise Over-Allotment Option for Ventrus Biosciences' Initial Public Offering NEW YORK, Jan. 7, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. ("Ventrus") (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced

Ventrus Biosciences Announces Closing of Initial Public Offering of Common Stock NEW YORK, Dec. 23, 2010 (GLOBE NEWSWIRE) -- Ventrus Biosciences Inc. ("Ventrus") (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that it

Ventrus Biosciences Announces Pricing of Its Initial Public Offering NEW YORK, Dec. 16, 2010 (GLOBE NEWSWIRE) -- Ventrus Biosciences Inc. ("Ventrus") (Nasdaq: VTUS ), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced the pricing of its